Though several trials are investigating the combination of CDK4/6 inhibition and anti-PD-1/PD-L1 therapy in advanced breast cancer (NCT02778685, NCT04360941), such an approach has to our knowledge not been attempted in NSCLC. Here, CDK4 is linked to breast cancer.